Axis Direct Broker Research reports

Asian Markets are mostly trading mixed as investors assess the US-China tariff truce extension overnight. The Nikkei and Shanghai are both trading positively, by 2.29% and 0.24%, respectively, whereas the Hang Seng is trading negatively by 0.16%.

We recommend a BUY on the stock with a TP of Rs 996 /share, implying a 10% upside from the CMP

We maintain our BUY rating on the stock with a target price of Rs 380/share, implying an 11% upside potential from the CMP.

We maintain a BUY rating on Medanta, supported by the expected recovery from temporary business disruptions, improvement in ARPOB, and incremental bed capacity addition, including the Noida hospital, which is likely to be operational by the end of H1FY26E.

We maintain our BUY recommendation on the stock.

We maintain our HOLD rating on the stock.

We maintain our BUY rating.

With a 32% upside from the CMP, we maintain our long-term BUY rating on the stock.

We maintain our BUY recommendation on reasonable valuations.

We revise our rating from BUY to HOLD